MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression - MIRASO

Immunogen, Inc.0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年9月9日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Immunogen, Inc.
入组人数: 10

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）

入选标准

•1. Female patients >= 18 years of age
•2. Patients must have a confirmed diagnosis of high-grade serous EOC, primary
•peritoneal cancer, or fallopian tube cancer
•3. Patients must have platinum-resistant disease
•a. Patients who have only had 1 line of platinum based therapy must have
•received at least 4 cycles of platinum, must have had a response (CR or PR) and
•then progressed between > 3 months and <= 6 months after the date last dose of
•b. Patients who have received 2 or 3 lines of platinum therapy must have
•progressed on or within 6 months after the date of the last dose of platinum
•Note: Progression should be calculated from the date of the last administered
•dose of platinum therapy to the date of the radiographic imaging showing
•progression.; Patients who are platinum-refractory during front-line treatment
•are excluded (see exclusion criteria)
•4. Patients must have progressed radiographically on or after their most recent
•line of therapy
•Note: Progression must be determined radiographically and/or by CA-125 GCIG
•progression criteria
•5. Patients must be willing to provide an archival tumor tissue block or
•slides, or undergo procedure to obtain a new biopsy using a low risk,
•medically routine procedure for immunohistochemistry (IHC) confirmation of FRa
•6. Patient's tumor must be positive for FRa expression as defined by the
•Ventana FOLR1 (FOLR-2.1) CDx assay
•7. Patients must have at least one lesion that meets the definition of
•measurable disease by RECIST v1.1 (radiologically measured by the
•Investigator)
•8. Patients must have received at least 1 but no more than 3 prior systemic
•lines of anticancer therapy, and for whom single-agent therapy
•is appropriate as the next line of treatment:
•a. Adjuvant ± neoadjuvant considered one line of therapy
•b. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered as
•part of the preceding line of therapy (ie, not counted
•independently)
•c. Therapy changed due to toxicity in the absence of progression will be
•considered as part of the same line (ie, not counted independently)
•d. Hormonal therapy will be counted as a separate line of therapy unless it was
•given as maintenance.
•9. Patient must have an Eastern Cooperative Oncology Group Performance Status
•(ECOG PS) of 0 or 1
•10. Time from prior therapy:
•a. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is
•b. Focal radiation completed at least 2 weeks prior to first dose of study drug
•11. Patients must have stabilized or recovered (Grade 1 or baseline) from all
•prior therapy-related toxicities
•12. Major surgery must be completed at least 4 weeks prior to first dose and
•have recovered or stabilized from the side effects of prior surgery
•13. Patients must have adequate hematologic, liver and kidney functions defined
•a. Absolute neutrophil count (ANC) >= 1.5 x 109/L (1,500/µL) without G-CSF in
•the prior 10 days or long-acting WBC growth factors in the prior 20 days
•b. Platelet count >= 100 x 109/L (100,000/µL) without platelet transfusion in
•the prior 10 days
另有 4 项未显示

排除标准

•1. Patients with endometrioid, clear cell, mucinous, or sarcomatous
•histology, mixed tumors containing any of the above histologies, or lowgrade
•or borderline ovarian tumor
•2. Patients with primary platinum-refractory disease, defined as disease that
•did not respond to (CR or PR) or has progressed within 3 months of the last
•dose of first line platinum-containing chemotherapy
•3. Patients with prior wide-field radiotherapy (RT) affecting at least 20% of
•the bone marrow
•4. Patients with > Grade 1 peripheral neuropathy per Common
•Terminology Criteria for Adverse Events (CTCAE)
•5. Patients with active or chronic corneal disorders, history of corneal
•transplantation, or active ocular conditions requiring ongoing
•treatment/monitoring such as uncontrolled glaucoma, wet age-related
•macular degeneration requiring intravitreal injections, active diabetic
•retinopathy with macular edema, macular degeneration, presence of
•papilledema, and /or monocular vision
•6. Patients with serious concurrent illness or clinically relevant active
•infection, including, but not limited to the following:
•a. Active hepatitis B or C infection (whether or not on active antiviral
•b. HIV infection
•c. Active cytomegalovirus infection
•d. Any other concurrent infectious disease requiring IV antibiotics within 2
•weeks before starting study drug
•Note: Testing at screening is not required for the above infections unless
•clinically indicated
•7. Patients with history of multiple sclerosis or other demyelinating disease
•and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
•8. Patients with clinically significant cardiac disease including, but not
•limited to, any one of the following:
•a. Myocardial infarction <= 6 months prior to first dose
•b. Unstable angina pectoris
•c. Uncontrolled congestive heart failure (New York Heart Association >
•d. Uncontrolled >= Grade 3 hypertension (per CTCAE)
•e. Uncontrolled cardiac arrhythmias
•9. Patients assigned to PLD stratum only:
•Left ventricular ejection fraction (LVEF) below the institutional limit of
•normal as measured by echocardiography (ECHO) or multigated
•acquisition (MUGA) scan
•10. Patients with a history of hemorrhagic or ischemic stroke within six
•months prior to randomization
•11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B
•12. Patients with a previous clinical diagnosis of non-infectious
•interstitial lung disease (ILD), including noninfectious pneumonitis
•13. Patients with required use of folate-containing supplements (eg, folate
•deficiency)
•14. Patients with prior hypersensitivity to monoclonal antibodies
•15. Women who are pregnant or lactating
•16. Patients with prior treatment with MIRV or other FRa-targeting agents
•17. Patients with untreated or symptomatic central nervous system
•(CNS) metastases
另有 8 项未显示

研究者

发起方

Immunogen, Inc.

相似试验

进行中（未招募）

1 期

A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor'schoice of cancer medicines in women with advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersAdvanced High-Grade Epithelial Ovarian, Primary Peritoneal, or FallopianTube Cancers with High Folate Receptor-Alpha ExpressionMedDRA version: 21.0Level: PTClassification code 10061269Term: Malignant peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-003509-80-PLImmunoGen, Inc.430

进行中（未招募）

1 期

EUCTR2019-003509-80-PTImmunoGen, Inc.430

进行中（未招募）

1 期

A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor'schoice of cancer medicines in women with advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

EUCTR2019-003509-80-GBImmunoGen, Inc.430

进行中（未招募）

1 期

A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor'schoice of cancer medicines in women with advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

EUCTR2019-003509-80-DEImmunoGen, Inc.430

进行中（未招募）

1 期

EUCTR2019-003509-80-NLImmunoGen, Inc.430